Doxycycline Hyclate (WC2031)

For research use only.

Catalog No.S4163 Synonyms: Doxycycline hydrochloride hemiethanolate hemihydrate

21 publications

Doxycycline Hyclate (WC2031) Chemical Structure

CAS No. 24390-14-5

Doxycycline Hyclate (WC2031, Doxycycline hydrochloride hemiethanolate hemihydrate) is a member of the tetracycline antibiotics group, and is commonly used to treat a variety of infections. It is also an inhibitor of matrix metallo-proteinases (MMP).

Selleck's Doxycycline Hyclate (WC2031) has been cited by 21 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Doxycycline Hyclate (WC2031, Doxycycline hydrochloride hemiethanolate hemihydrate) is a member of the tetracycline antibiotics group, and is commonly used to treat a variety of infections. It is also an inhibitor of matrix metallo-proteinases (MMP).
Targets
MMP [6]
In vitro

Doxycycline hyclate 10% (DOXY) has significant toxicity effects on osteoblast cells compared to the control group with a mean cell viability of 84%. Doxycycline hyclate 10% (DOXY) results in a significantly higher alkaline phosphatase activity (approximately 56%) than the control in osteoblasts. Doxycycline hyclate 10% (DOXY) seems to slightly altered the morphology of the osteoblasts. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SW1353 NX;Lb2Y1TnWwY4Tpc44h[XO|YYm= MXW1NEB2VQ>? MVLJcohq[mm2aX;uJI9nKEmOLUGtZoV1[S2rbnT1Z4VlKE2PUEGzJJBzd2S3Y4Tpc44hcW5iaIXtZY4hW1dzM{WzJINmdGy|IHH0JFUxKHWP NFHCZ3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{K2O|IzPyd-MUeyOlczOjd:L3G+
K-12 BW25113 NUjrdXJmSmGldHXybYNq\GGuIHHzd4F6 MmfaNlQhcHK| MU\CZYN1\XKrY3nkZYwh[WO2aY\peJkh[WejaX7zeEB6[W[TIHflcoUu\GWoaXPp[Y51KEW|Y3jldolkcGmjIHPvcIkhUy1zMjDCW|I2OTF|IHLpc4ZqdG1iYYPz[ZN{\WRiYYOgcI9oKHKnZIXjeIlwdiCxZjD2bYFjdGViY3XscJMh[W[2ZYKgNlQhcHK| M4HheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{C3N|c2Lz5zOUOwO|M4PTxxYU6=
K-12 BW25113 MYTCZYN1\XKrY3nkZYwh[XO|YYm= M3rpcFI1KGi{cx?= MmPaRoFkfGW{aXPp[IFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBMNTF{IFLXNlUyOTNiYnnv[oltdSCqYYLic5JqdmdicFPBNlRPKHC2YXO6Ppli\lFicHzhd41q\CCjc4Pld5Nm\CCjczDsc4chemWmdXP0bY9vKG:oII\pZYJt\SClZXzsd{Bi\nSncjCyOEBpenNicILleJJm[XSnZDD3bZRpKDVidV2gc4YhUVCWRzDmc5IhPCCqcoO= NYfIN45sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFc{PzVpPkG5N|A4Ozd3PD;hQi=>
K562 M3XmNGN6fG:2b4jpZ4l1gSCjc4PhfS=> MlXOO|IhcHK| MXPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDmcI94KGO7dH;t[ZRzgSxiSVO1NEA:KDF3IN88UU4> NXLMUVB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0PFI1PzZpPkG5OFgzPDd4PD;hQi=>
HepG2 NVnrT4JUS3m2b4TvfIlkcXS7IHHzd4F6 NGThTGk4OiCqcoO= NUTXTFRpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJyIN88UU4> MojtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2OEK0O|YoRjF7NEiyOFc3RC:jPh?=
THP1 MkHPSpVv[3Srb36gZZN{[Xl? M1vGbnNmdGWldHn2bZR6KGmwZHX4MEBz[XSrbzDv[kBKSzVyIH\vdkBpfW2jbjDUTHAyKGOnbHzzJJRwKEmFNUCg[o9zKFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTygTWM2OCB;IEOuNUDPxE1w MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEe4NUc,OTl5NEi3PFE9N2F-
THP1 MmO4R5l1d3SxeHnjbZR6KGG|c3H5 MnrFO|IhcHK| MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUTHAyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[ub4egZ5l1d22ndIL5MEBKSzVyIE2gNlAh|ryPLh?= M4j3WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4O|gyLz5zOUe0PFc5OTxxYU6=
K562 MUjDfZRwfG:6aXPpeJkh[XO|YYm= NVPQenYzPzJiaILz NILoWIlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFczKGi{czDifUBndG:5IHP5eI9u\XS{eTygTWM2OCB;IEG1JO69VS5? MnPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Mk[xO|MoRjF7OUK2NVc{RC:jPh?=
HepG2 MVLDfZRwfG:6aXPpeJkh[XO|YYm= NFTFNGI4OiCqcoO= NWDuO4QxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJyIN88UU4> M3K5[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUK2NVc{Lz5zOUmyOlE4OzxxYU6=
HepG2 NH35cVNEgXSxdH;4bYNqfHliYYPzZZk> MUW3NkBpenN? NETmVHdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOjBizszNMi=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd2MUGzNUc,OjF5NEGxN|E9N2F-
Neuro2a NYPYdpN5TnWwY4Tpc44h[XO|YYm= MXWxJJVO M1fBOGRm[3KnYYPlJIlvKDdvRFjDJIxmfmWuczDpckBFcGO{Nz3k[YZq[2mnboSgcY92e2ViTnX1do8z[SClZXzsd{BifCBzIIXNJIJ6KEyFLV3TM2dENU2VIHHuZYx6e2m| MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OU[1O{c,OjZ5OEm2OVc9N2F-
HepG2 MXHDfZRwfG:6aXPpeJkh[XO|YYm= NX76XFQzPzJiaILz NXfE[Y83S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiQ1O1NEA:KDJyIN88UU4> M2LtT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY{Lz5{N{G1OVQ3OzxxYU6=
HepG2 MWPDfZRwfG:6aXPpeJkh[XO|YYm= M13lSlczKGi{cx?= NHywN3pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygR2M2OCB;IEKwJO69VS5? Mn\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd4NUSzPVUoRjJ5NkW0N|k2RC:jPh?=
CD MnL4RY51cWKjY4TldolidCCjc4PhfS=> MUOyOUB2\y:vbB?= MofaO|IhcHK| MUjBcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhWmmla3X0eJNq[SCycn;3ZZpmc2mrIIP0dk4hSnKnaX7sJIlv\mWldHXkJIlvKEOGIILheEBxemmvYYL5JJB2dG2xbnHyfUB3[XOldXzhdkBmdmSxdHjlcIlidCClZXzsd{Bie3Onc4Pl[EBieyCkYXP0[ZJq[Wxic3jhdIUh[2ijbnflJIF1KDJ3IIXnM41tKG2nYYP1doVlKDd{IHjyd{Bxd3O2IHnu[oVkfGmxbjDifUBJd2WlaIP0JFM{OjV6L4DoZYxtd2mmaX6gd5RicW6rbnegZoF{\WRiZnz1c5I> NUXNbmJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwPFk{PTBpPkK4NFg6OzVyPD;hQi=>
A673 M2rJUpFJXFNiYYPzZZk> NHnLfXRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NFOyeos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-12 NXzoPGtveUiWUzDhd5NigQ>? MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? M{PSeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
skeletal myoblast cells MljZR5l1d3SxeHnjbZR6KGG|c3H5 MoTvSG5FUTpiQ4n0c5RwgGmlaYT5JIlvKF[rdILvMEA4OiCqb4XyMEBqdiC{YYSgd4tmdGW2YXygcZlw[myjc4SgZ4VtdHNuIFnDOVAhRSBzND60PUDPxE1w NGHXRoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDN|Lze+R4hGVUKOPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AKT / BCL6 / Cyclin E / HDAC2 / HDAC3 / NEMO / TYK2 / RIPK1; 

PubMed: 26142707     


Doxycycline treatment decreases the levels of HSP90 client proteins in DLBCL cells. The DLBCL cells were treated with the indicated concentrations of doxycycline for 24 hrs. The levels of HSP90 client proteins in these cells were analyzed by western blotting.

HSP70 / HSP90 ; 

PubMed: 26142707     


Reduced protein levels of HSP70 and HSP90 in DLBCL cells treated with doxycycline. DLBCL cells were treated with doxycycline for 24 hrs, and the levels of HSP70 and HSP90 were analyzed by western blotting. 

pATM / ATM ; 

PubMed: 23282955     


Levels of phosphorylated ATM and overall ATM was determined in the indicated cell lines at the indicated times after treatment with 1μg/ml doxycycline, as detected by Western Blotting.

26142707 23282955
Immunofluorescence
E-cadherin / Vimentin ; 

PubMed: 29285218     


Doxycycline increases E-cadherin expression and decreases Vimentin expression, whereas thrombin partly counteracts this inhibitory effect in MCF-7 cells.

29285218
In vivo Doxycycline hyclate is an effective treatment for acute E. canis infection in dogs. [2] Doxycycline hyclate (5 mg/kg, orally) decreases the collagenase activity in corneas obtained from rabbits. Doxycycline hyclate (5 mg/kg, orally) promotes corneal reepithelialization in the rabbit alkali-burn model, a result, perhaps, of the drug's ability to inhibit excessive collagenase activity. [3] Doxycycline hyclate results in 43% of prophylaxis in orally treated mice, in contrast, the sustained-release doxycycline hyclate completely protects mice from infection and resultant pathology. [4] Doxycycline hyclate results in bioavailability of 70%, Cmin of 1 mg/L, Cmax of 2.3 mg/L and elimination half-life of 7 hours in calves with immature rumen function. [5]

Protocol

Solubility (25°C)

In vitro DMSO 100 mg/mL (194.95 mM)
Water 100 mg/mL (194.95 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 512.94
Formula

C22H24N2O8.1/2C2H6O.HCl.1/2H2O

CAS No. 24390-14-5
Storage powder
in solvent
Synonyms Doxycycline hydrochloride hemiethanolate hemihydrate
Smiles CCO.CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04838717 Not yet recruiting Drug: BPG|Drug: Doxycycline Syphilis Assistance Publique - Hôpitaux de Paris May 2021 Phase 3
NCT04860505 Recruiting Drug: Doxycycline|Drug: Biktarvy Sexually Transmitted Diseases Emory University|Centers for Disease Control and Prevention May 20 2021 Phase 4
NCT04762134 Not yet recruiting Drug: Doxycycline Hyclate Bacterial Sexually Transmitted Diseases Jonathan Troy Grennan|Canadian Institutes of Health Research (CIHR)|British Columbia Centre for Disease Control April 1 2021 Phase 2|Phase 3
NCT04597424 Recruiting Drug: Experimental: doxycycline|Biological: Bexsero® vaccine Unsafe Sex|Risk-Taking ANRS Emerging Infectious Diseases January 19 2021 Phase 3
NCT04686799 Recruiting Drug: Doxycycline Hyclate 20 MG Lateral Epicondylitis|Lateral Epicondylitis Left Elbow|Lateral Epicondylitis Right Elbow|Lateral Epicondylitis Unspecified Elbow|Lateral Epicondylitis (Tennis Elbow) Bilateral Hospital for Special Surgery New York December 3 2020 Phase 1
NCT04269434 Active not recruiting Other: No Screening Neisseria Gonorrhoeae Infection|Chlamydia Trachomatis Infection Institute of Tropical Medicine Belgium September 21 2020 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Doxycycline Hyclate (WC2031) | Doxycycline Hyclate (WC2031) supplier | purchase Doxycycline Hyclate (WC2031) | Doxycycline Hyclate (WC2031) cost | Doxycycline Hyclate (WC2031) manufacturer | order Doxycycline Hyclate (WC2031) | Doxycycline Hyclate (WC2031) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID